We are live on ! Find out more
CATX icon

Perspective Therapeutics

105 hedge funds and large institutions have $385M invested in Perspective Therapeutics in 2024 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 33 increasing their positions, 16 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

106% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 16

52.32% more ownership

Funds ownership: 5.01%57.32% (+52%)

30% more capital invested

Capital invested by funds: $296M → $385M (+$88.9M)

2% more funds holding

Funds holding: 103105 (+2)

8% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 48

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
105
Holders Change
+2
Holders Change %
+1.94%
% of All Funds
1.52%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
52
Increased
33
Reduced
16
Closed
48
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CC
1
Commodore Capital
New York
$46.4M +$36.9M +2,552,082 +121%
Janus Henderson Group
2
Janus Henderson Group
United Kingdom
$44M +$45.3M +3,134,719 +239%
BlackRock
3
BlackRock
New York
$34.8M +$39M +2,696,477 +342%
APM
4
Avidity Partners Management
Texas
$30.3M +$43.9M +3,037,668 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$29.1M +$16.5M +1,143,257 +64%
DM
6
Deerfield Management
New York
$28.1M -$14 -1 -0%
OCA
7
Octagon Capital Advisors
New York
$15.8M +$1.57M +108,407 +7%
Marshall Wace
8
Marshall Wace
United Kingdom
$12.8M -$8.87M -613,231 -32%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$10.3M +$8.63M +596,982 +136%
State Street
10
State Street
Massachusetts
$9.94M +$12.1M +839,185 +530%
GTC
11
Ghost Tree Capital
New York
$9.22M +$4.7M +325,000 +54%
PBA
12
Paradigm Biocapital Advisors
New York
$9.17M +$13.3M +919,692 New
SFM
13
Sphera Funds Management
Israel
$7.85M -$6.61M -457,453 -37%
ECM
14
ExodusPoint Capital Management
New York
$5.94M +$4.44M +307,160 +106%
Citadel Advisors
15
Citadel Advisors
Florida
$5.74M -$9.41M -651,194 -53%
AAA
16
Affinity Asset Advisors
New York
$5.48M +$578K +40,000 +8%
SSA
17
Schonfeld Strategic Advisors
New York
$5.24M +$3.51M +242,760 +86%
Walleye Capital
18
Walleye Capital
New York
$5.11M +$7.41M +512,823 New
O
19
OrbiMed
New York
$4.91M -$2.28M -157,910 -24%
RSCM
20
Rock Springs Capital Management
Maryland
$4M +$5.8M +401,196 New
ABG
21
Ally Bridge Group
New York
$3.95M +$5.73M +396,242 New
Adage Capital Partners
22
Adage Capital Partners
Massachusetts
$3.8M +$5.52M +381,640 New
SC
23
Stempoint Capital
New York
$3.43M +$4.97M +343,810 New
EAM
24
Eagle Asset Management
Florida
$2.71M +$3.49M +241,679 New
N
25
Nuveen
North Carolina
$2.6M +$3.77M +260,927 New

CATX Hedge Fund Activity: Q2 2024 in Review

105 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q2 2024, worth a combined $385M — up 30% from $296M a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new CATX positions and 48 closed out — a net gain of 4 holders — while 33 added to existing stakes and 16 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $45.3M. The largest seller was Point72 Asset Management, cutting an estimated $16.5M.

  • 105 institutional investors held Perspective Therapeutics (CATX) as of Q2 2024, up from 103 in Q1 2024.
  • Funds reported $385M of Perspective Therapeutics stock for Q2 2024, up 30% quarter-over-quarter.
  • 52 funds opened new Perspective Therapeutics positions in Q2 2024 and 48 closed out, a net change of +4 holders.
  • The largest Perspective Therapeutics buyer in Q2 2024 was Janus Henderson Group, an estimated $45.3M added.
  • The largest Perspective Therapeutics seller in Q2 2024 was Point72 Asset Management, an estimated $16.5M sold.

Based on aggregated 13F filings for Q2 2024.